BI
ELEV

BVF Inc’s Elevation Oncology ELEV Stock Holding History

BVF Inc’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,966,836
Closed -$1.67M – 53
2024
Q4 		$1.67M Hold
2,966,836
– – 0.06% 50
2024
Q3 		$1.78M Buy
2,966,836
+654,636
+28% +$971K 0.05% 48
2024
Q2 		$6.24M Hold
2,312,200
– – 0.18% 43
2024
Q1 		$11.9M Hold
2,312,200
– – 0.33% 37
2023
Q4 		$1.24M Hold
2,312,200
– – 0.03% 67
2023
Q3 		$1.53M Hold
2,312,200
– – 0.04% 67
2023
Q2 		$3.51M Hold
2,312,200
– – 0.1% 57
2023
Q1 		$4.39M Hold
2,312,200
– – 0.16% 59
2022
Q4 		$2.19M Hold
2,312,200
– – 0.09% 66
2022
Q3 		$2.61M Hold
2,312,200
– – 0.11% 66
2022
Q2 		$3.24M Buy
2,312,200
+2
+0% +$5 0.16% 64
2022
Q1 		$5.83M Buy
2,312,198
+700,500
+43% +$2.81M 0.23% 64
2021
Q4 		$9.7M Buy
1,611,698
+21,400
+1% +$148K 0.35% 54
2021
Q3 		$12.4M Buy
1,590,298
+7
+0% +$76 0.48% 51
2021
Q2 		$21.6M Buy
+1,590,291
New +$19.7M 0.81% 33

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BVF Inc's ELEV Position: Q1 2025 in Review

BVF Inc sold out of Elevation Oncology (ELEV) in Q1 2025, closing a stake of 2,966,836 shares — an estimated $1.67M sold.

BVF Inc first reported a position in ELEV in Q2 2021 and held it in 15 quarters. The position peaked at $21.6M in Q2 2021. 72 funds tracked by Wall St. Rank hold ELEV as of Q1 2025.

  • BVF Inc reported no remaining Elevation Oncology position as of Q1 2025 after selling out during the quarter.
  • BVF Inc sold 2,966,836 Elevation Oncology shares in Q1 2025, an estimated $1.67M.
  • BVF Inc first reported a position in Elevation Oncology in Q2 2021 and held it in 15 quarters.
  • BVF Inc's Elevation Oncology position peaked at $21.6M in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Elevation Oncology as of Q1 2025.

Based on BVF Inc's 13F filing for Q1 2025, filed 15 May 2025.